Capnia Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc stock price live, this page displays NASDAQ SLNO stock exchange data. View the SLNO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Soleno Therapeutics Inc real time stock price chart below.
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 52.6700.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is "SLNO."
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 52.6700.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is "SLNO."
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.6500
52.7700
52 wk Range
29.4300
90.3199
SLNO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.650052.7700
52 wk Range
29.430090.3199
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLNO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
53.0000
Upside
+0.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Capnia Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form PRE 14A Soleno Therapeutics Inc For: 10 April
- Investing.com
- Capnia Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form PRE 14A Soleno Therapeutics Inc For: 10 April
- Investing.com
- Capnia Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics Inc SWOT Analysis
VYKAT XR Breakthrough | Explore Soleno's FDA-approved treatment for Prader-Willi Syndrome, addressing hyperphagia in a 12,000-patient U.S. market with potential global expansion |
Market Dynamics | Delve into VYKAT XR's commercial launch, pricing strategy, and early adoption metrics, with analysts projecting peak sales of up to $2.8 billion worldwide |
Financial Outlook | Discover Soleno's strong cash position of $290 million and analyst expectations of profitability, with EPS forecasts of $6.65 for FY2025 |
Analyst Consensus | Learn about the "Strong Buy" recommendation and median price target suggesting 37% upside, with targets ranging from $20 to $145 per share |
Soleno Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 EPS of $0.80 beat estimates by 31%, revenue hit $91.7M vs. $82.45M expected; stock rose 4.72% aftermarket to $39.28
- Net income reached $43.4M vs. $56M loss in Q4 2024, driven by successful VYKAT XR launch for Prader-Willi syndrome treatment
- Strong balance sheet with $506.1M cash and current ratio of 16.08; liquid assets substantially exceed short-term obligations
- Company projects continued EPS and revenue growth through 2026; analysts forecast profitability with expanding net income this year
- Management focuses on expanding U.S. market share and pursuing EU regulatory approval; risks include supply chain issues and market saturation
Last Updated: 2026-02-25, 05:38 p/m
Read Full TranscriptCompare SLNO to Peers and Sector
Metrics to compare | SLNO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 133.3x | −3.5x | −0.5x | |
PEG Ratio | 1.22 | −0.50 | 0.00 | |
Price/Book | 6.1x | 5.3x | 2.6x | |
Price / LTM Sales | 14.3x | 24.4x | 3.2x | |
Upside (Analyst Target) | 0.6% | 67.7% | 44.2% | |
Fair Value Upside | Unlock | 3.6% | 5.5% | Unlock |
Analyst Ratings
0 Buy
11 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 53.0000
(+0.63% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
0.80 / 0.61
Revenue / Forecast
91.73M / 82.45M
People Also Watch
FAQ
What Is the Soleno Therapeutics (SLNO) Stock Price Today?
The Soleno Therapeutics stock price today is 52.6700 USD.
What Stock Exchange Does Soleno Therapeutics Trade On?
Soleno Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Soleno Therapeutics?
The stock symbol for Soleno Therapeutics is "SLNO."
What Is the Soleno Therapeutics Market Cap?
As of today, Soleno Therapeutics market cap is 2.7300B USD.
What Is Soleno Therapeutics's Earnings Per Share (TTM)?
The Soleno Therapeutics EPS (TTM) is 0.3900.
When Is the Next Soleno Therapeutics Earnings Date?
Soleno Therapeutics will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is SLNO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Soleno Therapeutics Stock Split?
Soleno Therapeutics has split 2 times.
How Many Employees Does Soleno Therapeutics Have?
Soleno Therapeutics has 182 employees.
What is the current trading status of Soleno Therapeutics (SLNO)?
As of Apr 21, 2026, Soleno Therapeutics (SLNO) is trading at a price of 52.6700 USD, with a previous close of 52.7800 USD. The stock has fluctuated within a day range of 52.6500 USD to 52.7700 USD, while its 52-week range spans from 29.4300 USD to 90.3199 USD.
What Is Soleno Therapeutics (SLNO) Price Target According to Analysts?
The average 12-month price target for Soleno Therapeutics is 53.0000 USD, with a high estimate of 53 USD and a low estimate of 53 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +0.63% Upside potential.
What Is the SLNO Premarket Price?
SLNO's last pre-market stock price is 52.7900 USD. The pre-market share volume is 8,780.0000, and the stock has decreased by 0.0100, or 0.0200%.
What Is the SLNO After Hours Price?
SLNO's last after hours stock price is 52.7700 USD, the stock has decreased by 0.1000, or 0.1900%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.